Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

Many patients with autoimmune blistering skin disorders change their diets, avoiding foods like alcohol, citrus, and spices, and some find vegetables and dairy helpful.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Tofacitinib treatment for hair loss may worsen acne.

Alopecia areata negatively impacts quality of life and work, even with moderate hair loss.

Eczema patients have a lower skin lipid to protein ratio, older and longer-staying hospital patients are more likely to get pressure ulcers, hair loss in AGA is linked to muscle degeneration, vitamin D deficiency is common in alopecia areata and linked to its severity, standard liver tests don't effectively detect fibrosis in psoriasis patients on methotrexate, and bullous pemphigoid patients have a higher death risk but combination therapy may reduce it.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Alopecia areata affects quality of life more than androgenetic alopecia.

Baricitinib is effective and safe for treating severe alopecia areata.

High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.

High-dose intravenous iron therapy doesn't interfere with treatment improvements in IBD patients with iron deficiency anemia.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Baricitinib is more effective than methotrexate for severe alopecia areata.

Children with different rheumatologic diseases have specific skin symptoms that can help with diagnosis.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

The Turkish version of the MAIA-2 Scale is valid and reliable for patients at a dermatology clinic.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

The IPP index is linked to storage symptoms and leftover urine, and may help manage urinary tract symptoms.

The document concludes that Hidradenitis suppurativa is often underdiagnosed, lacks definitive treatment, and requires better awareness and management strategies.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.

Tofacitinib is a promising treatment for children with rheumatic diseases.

The guideline recommends using specific drugs and surgery together for treating hidradenitis suppurativa effectively.

The Brazilian version of the Alopecia Areata Quality of Life Index is reliable for assessing patients' quality of life.

Polygenic Score can help predict severe psoriasis and psoriatic arthritis.